Nano-Based Technology for Glioblastoma

Dear Colleagues,

Nano-based technology offers promising avenues for treating glioblastoma, the most common and deadliest form of primary brain cancer in adults. Innovative approaches utilizing nanoparticles to deliver therapeutic agents directly to tumor cells have been successfully designed to enhance drug efficacy while minimizing off-target effects. Nanoparticles can not only penetrate the blood–brain barrier, allowing for targeted drug delivery to tumor cells, but can also be engineered to release drugs in response to specific stimuli within the tumor microenvironment. The goal of these platforms is to reduce systemic toxicity, while also enabling combination therapies, by delivering multiple drugs simultaneously to avoid drug resistance and improve treatment efficacy. Overall, nano-based technology holds immense potential for revolutionizing glioblastoma therapy, offering hope for improved patient outcomes and survival rates.

Under this scope, we are pleased to invite you to participate in the Special Issue of Pharmaceutics, entitled “Nano-Based Technology for Glioblastoma Therapy.” This Special Issue aims to include original research articles and reviews within, but not limited to, the following research areas: design and development of nanoparticles that specifically target glioblastoma cells; strategies to enhance the ability of nanoparticles to penetrate the blood–brain barrier; engineering stimuli-responsive nanoparticles or immunomodulatory nanoparticles; nano-delivery platforms for combination therapies; imaging, diagnosis, and theranostics with nano-based systems, among others.

We look forward to receiving your contributions.

Dr. Maria João Ramalho
Dr. Joana Peixoto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• nanoparticles
• glioblastoma
• blood–brain barrier
• diagnosis
• therapy
• drug delivery
• nose-to-brain delivery
• targeted delivery
• surface modification